Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Targeted Protein Degradation | Industry Spotlights & Insight Articles

Talking TPD with Ben Cross, CTO and Head of Platform at PhoreMost

Edited by Tom Cohen | 22 November 2023
Delving into PhoreMost's role in targeted protein degradation, the innovation behind the SITESEEKER platform, and the challenges and breakthroughs in the dynamic field of drug discovery.
https://www.youtube.com/watch?v=tuUuCBLDw3Y&ab_channel=OxfordGlobal

Like this interview? See more like it below:

Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation
and HIT optimisation of small and large molecule drugs.

Speaker Biographies

Benedict Cross is CTO at PhoreMost, a next-generation target and drug discovery company. He joined in 2019 to lead the evolution and development of the SITESEEKER® screening platform which uses PROTEINi to discover new drugs. Before PhoreMost, Ben founded and led the CRISPR-based functional genomic screening department at the leading UK gene editing biotech, Horizon Discovery. He is a geneticist and biotechnologist, with over ten years of professional research and management experience and has a background in proteostasis and chemical genetic screening

Related Resources

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.
Read More

Targeting Novel E3 Ubiquitin Ligases: Carles Galdeano, Professor, University of Barcelona

We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics.
Read More